Drug /Cue Interactions In Alcohol-Tobacco Comorbidity
This trial is active, not recruiting.
|Treatment||tobacco research and intervention program|
|Sponsor||H. Lee Moffitt Cancer Center and Research Institute|
|Collaborator||National Institutes of Health (NIH)|
|Start date||May 2006|
|End date||March 2014|
|Trial size||244 participants|
|Trial identifier||NCT00816231, MCC-14671|
The purpose of this study is to determine how people react to different combinations of alcohol and nicotine.
|Intervention model||single group assignment|
|Masking||double blind (subject, investigator)|
Psychophysiological Reactivity Assessment
time frame: approximately 5 weeks per participant
Alcohol Self-administration Assessment
time frame: approximately 5 weeks per participant.
Male or female participants from 21 years up to 55 years old.
Inclusion Criteria: - English speaking persons who exhibit a range of alcohol consumption and smoking patterns. - Signed written consent form. Exclusion Criteria: - Females who are pregnant, nursing, or not using effective methods of birth control will be excluded from participating.
|Official title||Drug /Cue Interactions In Alcohol-Tobacco Comorbidity|
|Principal investigator||David Drobes, Ph.D.|
|Description||The present project will improve and expand upon previously published work in several ways. First, Study 1 will assess reactivity to alcohol and smoking cues in the same session. Second, both studies will include within-subjects design factors to manipulate alcohol and nicotine intake, as well as cue types. Third, craving indices will represent three important response domains: subjective, physiological, and behavioral (e.g., Niaura et al., 1991). Fourth, each study will evaluate a range of drinkers and smokers, which will provide maximal information concerning influences on alcohol and smoking cue reactivity across various subject populations. The proposed studies are not only important from a theory development perspective, but they will provide an excellent foundation for future laboratory-based and clinical research.|
Call for more information